9 October 2015 - Huseyin Naci and colleagues call for improvements in the regulatory standards for licensing, reimbursing, and adopting new preventive drugs to ensure that treatments for type 2 diabetes really benefit patients.

For more details, go to: http://www.bmj.com/content/351/bmj.h5260?etoc=